NCT04984720

Brief Summary

Migraine is a common headache disorder and affects 1 in 5 adults during their lifetime. It is a disorder which leads to significantly impaired quality of life, absence from work, loss of productivity in workplace and reduced vitality in social functioning. One of the important cornerstones in the management of migraine is the maintenance of a good headache diary. A headache diary enables the physician to understand the headache characteristics as well to establish the triggers causing the precipitation of episodes. The other important measure to ensure good outcomes is compliance to medications in those who have been prescribed prophylaxis. Migraine prophylaxis is by pills that have to be taken everyday at fixed time to ensure best outcomes. However, it is known that patients with migraine often are not adherent to prophylactic medications. A meta-analysis of 33 studies found that observational studies (n = 14) showed adherence ranging from 41% to 95% at 2 months after initiation of medication and 21% to 80% at 6 months. Pooled rates of persistence derived from 19 RCTs on propranolol, amitriptyline, and topiramate showed adherence rates of 77%, 55%, and 57%, respectively, at 16-26 weeks of initiation. The real world adherence is expected to be lower than that in the ideal settings of randomized trials. Regular pill reminders issued through smartphone based applications can improve medication adherence and thus improve headache outcomes. Though smartphone based migraine tracker digital applications are available, they mostly are aimed at capturing headache characteristics. The efficacy of providing pill reminders along with patient educational materials and community blog to enable migraineurs share their experiences with each other has not been studied in controlled trials. It is known that patients who are well informed about their chronic diseases such as migraine often have better outcomes. Busy clinicians often resort to providing pamphlets regarding the disease, triggers, acute pain relief medications, prophylactic therapy etc. However, it is yet to be studied if a digital application with all these inbuilt features, which are easily accessible at the finger tips would lead to better information uptake and improved compliance and self management. This RCT would try to assess this gap in knowledge.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
400

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jul 2021

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 18, 2021

Completed
7 days until next milestone

Study Start

First participant enrolled

July 25, 2021

Completed
5 days until next milestone

First Posted

Study publicly available on registry

July 30, 2021

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2022

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 31, 2023

Completed
Last Updated

July 30, 2021

Status Verified

July 1, 2021

Enrollment Period

1.4 years

First QC Date

July 18, 2021

Last Update Submit

July 29, 2021

Conditions

Keywords

Mobile phone applicationBehavioural interventionHeadache outcomesMedication adherenceQuality of life

Outcome Measures

Primary Outcomes (2)

  • Change in HIT-6 (Headache impact test-6) score

    To compare the change in HIT-6 (Headache impact test-6 ranges from 36-78 with a higher score indicating greater severity) score from baseline to 4 weeks after introduction of the digital smartphone based application vs paper-pen diary.

    4 weeks

  • Reduction in headache days

    To compare the percentage of patients reporting 30 % or more reduction in headache days at 4 weeks following introduction of digital smart phone based application vs paper-pen diary .

    4 weeks

Secondary Outcomes (11)

  • Compliance

    4 weeks

  • Number of headache days per 28 days

    4 weeks

  • Change in number of headache days per 28 days from baseline

    4 weeks

  • change from baseline in the number of days with severe headaches per 28 days

    4 weeks

  • Change from baseline in the duration of headache episodes in the preceding 4 weeks

    4 weeks

  • +6 more secondary outcomes

Study Arms (2)

Smart phone based digital app arm

EXPERIMENTAL

Digital smartphone application which tracks migraine and to offers pill reminders for medication adherence and community blog and disease related educational material for migraineurs will be given to the patients

Behavioral: Smartphone based digital application

Paper and pen diary arm

ACTIVE COMPARATOR

Clinic based education and traditional paper-pen diary will be administered in tracking headache parameters

Behavioral: Smartphone based digital application

Interventions

Smartphone Based Digital Application to Track Migraine, Offer Pill Reminders for Medication Adherence and Community Blog

Also known as: Paper pen diary
Paper and pen diary armSmart phone based digital app arm

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult patients attending neurology OPD.
  • At least 18 years of age; any gender.
  • Episodic or chronic migraine diagnosed (using International Classification of Headache Disorders-3 (ICHD-3) .
  • No modifications to the prophylactic therapy or acute pain relief medications is planned over the next 3 months.
  • Can read and write in Hindi or English easily.
  • Have an Android/iOS smart phone in which digital application can be installed and who knows how to operate smart phone.
  • Ready to provide consent and willing to adhere to protocol and comply with follow up visits.
  • No major neurological or systemic medical condition that reduces life expectancy to less than 1 year based on clinical prediction scores.

You may not qualify if:

  • Not willing to adhere to protocol.
  • Not willing to provide consent.
  • Inability or unwillingness to complete diary recording.
  • Patients with Medication over use headache ( as per ICHD -3).
  • Other primary headaches and secondary headache disorders.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

All India Institute of Medical Sciences, New Delhi

New Delhi, National Capital Territory of Delhi, 110029, India

Location

MeSH Terms

Conditions

Migraine DisordersMedication Adherence

Condition Hierarchy (Ancestors)

Headache Disorders, PrimaryHeadache DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesPatient CompliancePatient Acceptance of Health CareTreatment Adherence and ComplianceHealth BehaviorBehavior

Central Study Contacts

Arunmozhimaran Elavarasi, MD DM

CONTACT

Padma Srivastava MV, MD DM

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
The participant, investigator and care provider will be aware of the intervention and the sequence in which it is administered. The outcomes will be assessed by an outcome assessor who will not be aware of the arm into which the participant was randomized prior to the assessment.
Purpose
TREATMENT
Intervention Model
CROSSOVER
Model Details: * A run-in period of 4 weeks prior to randomization to optimize therapy and to document the baseline frequency and severity of headaches. * At the end of run-in period, the patients will be randomly allocated into the smartphone based digital App first arm or the paper diary first arm. The digital app and paper diary- are available in Hindi as well as English. * Randomization will be done by computer generated random number table. * Concealment: The sequence of allocation will be held concealed by opaque sealed envelopes. * Participant and investigator both will be aware of the allocated group - it is an open label study. * Participants will be followed up at 4 weeks and the headache characteristics and outcome parameters would be captured from the app and paper diary respectively. * Subsequently patients would be crossed over to the other arm and 4 weeks after the cross over, parameters would again be assessed.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor, Department of Neurology

Study Record Dates

First Submitted

July 18, 2021

First Posted

July 30, 2021

Study Start

July 25, 2021

Primary Completion

December 31, 2022

Study Completion

January 31, 2023

Last Updated

July 30, 2021

Record last verified: 2021-07

Data Sharing

IPD Sharing
Will share

On reasonable request from the investigator through our AIIMS Institute ethics committee, the individual participant data will be made available to other researchers

Shared Documents
STUDY PROTOCOL, CSR
Time Frame
will be available within 6 weeks for as long as suggested by our institute ethics committee
Access Criteria
Request to be made through the Institute ethics committee and would be processed as per Institute rules

Locations